摘要
目的探讨哌罗匹隆与氨磺必利对首发女性精神分裂症患者的临床疗效及安全性。方法将100例首发女性精神分裂症患者随机分为哌罗匹隆组和氨磺必利组各50例,分别给予哌罗匹隆和氨磺必利治疗,分别于治疗前和治疗后第8周末应用阳性和阴性综合征量表(PANSS)及治疗中需处理的不良反应症状量表(TESS)进行评分,在治疗12个月末采用生存质量测定量表(QOL-100)量表评定患者的生活质量。结果治疗后第8周末,两组总有效率比较差异无统计学意义(P>0.05),哌罗匹隆组总不良反应发生率(22.00%)低于氨磺必利组(48.00%)(P<0.05)。治疗12个月末,哌罗匹隆组QOL-100量表总分高于氨磺必利组(P<0.05)。结论哌罗匹隆与氨磺必利对首发女性精神分裂症患者均有较好疗效,但哌罗匹隆的不良反应发生率更低,患者治疗后生活质量更高。
Objective To explore the efficacy of perospirone and amisulpride in treatment of female patients with schizophrenia in first-episode. Methods A total of 100 female patients with schizophrenia in first - episode were randomly divided into perospirone group with perospirone and amisulpride group with amisulpride for treatment of 8 weeks. They were assessed with positive and negative symptom scale （PANSS） and side effects scale （TESS） before treatment and in the 8th weekend of treatment, quality of life scale （QOL-100）in the 12th month end after treatment. Results In the 8th weekend of treatment, there was no difference in the total effective rate between perospirone group（88% ） and amisulpride group（ 86% ） （P 〉0.05）, but the rate of side effects in perospirone group were significantly less than those in amisulpride group（P 〈0.05）. In the 12th month end after treatment, the total scores of QOL-100 in perospirone group were significantly more than those in amisulpride group （ P 〈 0. 05 ）. Conclusion It＇ s effective for perospirone and amisulpride to treat the female patients with schizophrenia in first-episode, but perospirone is more safe and helpful to improve the quality of life in the patients.
出处
《精神医学杂志》
2015年第3期192-194,共3页
Journal of Psychiatry
基金
广东省江门市科技计划项目(编号:江科[2009]76号)
